Review of the Treatment of Mycosis Fungoides and Sézary Syndrome: A Stage-Based Approach

View More View Less
  • a From Memorial Sloan-Kettering Cancer Center, New York, New York; Duke University, Durham, North Carolina; M. D. Anderson Cancer Center, Houston, Texas; Ohio State University, Columbus, Ohio; and Stanford University, Stanford, California.

The NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Disease were recently revised to include recommendations for treating mycosis fungoides and Sézary syndrome. These uncommon lymphomas require a specialized evaluation and use a unique TNMB staging system. Unlike the other forms of non-Hodgkin's lymphomas, stage overwhelmingly determines prognosis and defines radically different treatment approaches. For patients with early-stage disease, initial treatment with skin-directed therapies is preferred, and many patients never require systemic therapy. For patients with refractory or advanced-stage disease, biologic therapies are often the first choices, whereas chemotherapies are reserved for later in the disease course. Many milder therapies may be repeated several times in the disease course, and maintenance and tapering strategies are common. This article also discusses the emerging role of allogeneic stem cell transplantation.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Steven M. Horwitz, MD, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. E-mail: horwitzs@mskcc.org
  • 1.

    Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973–2002. Arch Dermatol 2007;143:854859.

  • 2.

    Willemze R, Jaffe ES, Burg G. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:37683785.

  • 3.

    Kim YH, Liu HL, Mraz-Gernhard S. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic risk factors for disease progression. Arch Dermatol 2003;139:857866.

    • Search Google Scholar
    • Export Citation
  • 4.

    Zelenetz AD, Advani RH, Byrd JC. NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas, v. 1.2008. Last accessed: 14 February 2008.

    • Search Google Scholar
    • Export Citation
  • 5.

    Olsen E, Vonderheid E, Pimpinelli N. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007;110:17131722.

    • Search Google Scholar
    • Export Citation
  • 6.

    Pimpinelli N, Olsen EA, Santucci M. Defining early mycosis fungoides. J Am Acad Dermatol 2005;53:10531063.

  • 7.

    Vonderheid E, Bernengo MG. The Sezary syndrome: hematologic criteria. Hematol Oncol Clin N Amer 2003;17:13671389.

  • 8.

    Vonderheid EC, Bernengo MG, Burg C. Update on erythrodermic cutaneous T-cell lymphoma: report of the international society for cutaneous lymphomas. J Am Acad Dermatol 2002;46:95106.

    • Search Google Scholar
    • Export Citation
  • 9.

    Zackheim HS, Amin S, Kashani-Sabet M, McMillan A. Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad Dermatol 1999;40:418425.

    • Search Google Scholar
    • Export Citation
  • 10.

    van Doorn R, Van Haselen CW, van Voorst Vader PC. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 2000;136:504510.

    • Search Google Scholar
    • Export Citation
  • 11.

    Diamandidou E, Colome M, Fayad L. Prognostic factor analysis in mycosis fungoides/Sézary syndrome. J Am Acad Dermatol 1999;40:914924.

  • 12.

    Vergier B, de Muret A, Beylot-Barry M. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas. Blood 2000;95:22122218.

    • Search Google Scholar
    • Export Citation
  • 13.

    van Doorn R, Scheffer E, Willemze R. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients. Arch Dermatol 2002;138:191198.

    • Search Google Scholar
    • Export Citation
  • 14.

    Diamandidou E, Colome-Grimmer M, Fayad L. Transformation of mycosis fungoides/Sézary syndrome: clinical characteristics and prognosis. Blood 1998;92:11501159.

    • Search Google Scholar
    • Export Citation
  • 15.

    Olsen EA, Kim YH, Kuzel TM. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25:31093115.

    • Search Google Scholar
    • Export Citation
  • 16.

    Olsen E, Duvic M, Frankel A. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001;19:376388.

    • Search Google Scholar
    • Export Citation
  • 17.

    Duvic M, Hymes K, Heald P. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001;19:24562471.

    • Search Google Scholar
    • Export Citation
  • 18.

    Straus DJ, Duvic M, Kuzel T. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. Cancer 2007;109:17991803.

    • Search Google Scholar
    • Export Citation
  • 19.

    McGinnis KS, Junkins-Hopkins JM, Crawford G. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms. J Am Acad Dermatol 2004;50:375379.

    • Search Google Scholar
    • Export Citation
  • 20.

    Vonderheid EC, Bigler RD, Greenberg AS. Extracorporeal photopheresis and recombinant interferon alfa 2b in Sézary syndrome. Use of dual marker labeling to monitor therapeutic response. Am J Clin Oncol 1994;17:255263.

    • Search Google Scholar
    • Export Citation
  • 21.

    McGinnis KS, Ubriani R, Newton S. The addition of interferon gamma to oral bexarotene therapy with photopheresis for Sézary syndrome. Arch Dermatol 2005;141:11761178.

    • Search Google Scholar
    • Export Citation
  • 22.

    Gottlieb SL, Wolfe JT, Fox FE. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution. J Am Acad Dermatol 1996;35:946957.

    • Search Google Scholar
    • Export Citation
  • 23.

    Kaye FJ, Bunn PA Jr, Steinberg SM. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989;321:17841790.

    • Search Google Scholar
    • Export Citation
  • 24.

    Bunn PA Jr, Fischmann AB, Schechter GP. Combined modality therapy with electron-beam irradiation and systemic chemotherapy for cutaneous T-cell lymphomas. Cancer Treat Rep 1979;63:713717.

    • Search Google Scholar
    • Export Citation
  • 25.

    Wollina U, Dummer R, Brockmeyer NH. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 2003;98:9931001.

    • Search Google Scholar
    • Export Citation
  • 26.

    Duvic M, Talpur R, Wen S. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 2006;7:5158.

  • 27.

    Lundin J, Hagberg H, Repp R. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome. Blood 2003;101:42674272.

    • Search Google Scholar
    • Export Citation
  • 28.

    Bernengo MG, Quaglino P, Comessatti A. Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients. Haematologica 2007;92:784794.

    • Search Google Scholar
    • Export Citation
  • 29.

    Querfeld C, Rosen ST, Guitart J. Alemtuzumab (Campath-1H) in patients with erythrodermic cutaneous t-cell lymphoma (E-CTCL): the Northwestern University experience [abstract]. Blood 2006;108: Abstract 2732.

    • Search Google Scholar
    • Export Citation
  • 30.

    Molina A, Zain J, Arber DA. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. J Clin Oncol 2005;23:61636171.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 456 173 11
PDF Downloads 278 158 14
EPUB Downloads 0 0 0